Welcome to our dedicated page for Electrocore news (Ticker: ECOR), a resource for investors and traders seeking the latest updates and insights on Electrocore stock.
electroCore, Inc. (ECOR) is a leader in non-invasive vagus nerve stimulation therapies, providing innovative solutions for neurological conditions and wellness applications. This page serves as the definitive source for ECOR news, offering investors and professionals timely updates on regulatory developments, clinical research, and strategic initiatives.
Access curated press releases covering FDA clearances, partnership announcements, and financial results. Stay informed about advancements in gammaCore™ therapies for migraine treatment and TAC-STIM cognitive enhancement technologies. Our repository includes updates on international expansions, clinical trial outcomes, and product pipeline developments.
Bookmark this page for direct access to primary source materials from electroCore, including neuromodulation research breakthroughs and commercialization progress across healthcare and defense sectors. Regular updates ensure you maintain current awareness of ECOR's position in the evolving bioelectronic medicine landscape.
electroCore (Nasdaq: ECOR) announced a new reseller agreement with Red One Medical Devices, enhancing the availability of its gammaCore therapy within the federal marketplace. This collaboration targets U.S. Department of Veterans Affairs and Department of Defense hospitals, aiming to provide support to military personnel suffering from severe headaches. The partnership is set to streamline procurement processes, facilitating quicker access to gammaCore’s non-invasive vagus nerve stimulation therapy, which is designed for migraine and cluster headache relief.
electroCore, Inc. (Nasdaq: ECOR) announced the publication of a study in the Journal of Affective Disorders Reports, highlighting the effects of non-invasive vagus nerve stimulation (nVNS) on PTSD symptoms. Conducted at Georgia Tech and Emory University, the randomized trial showed a significant 31% reduction in PTSD symptoms and improvement in hyperarousal through nVNS after three months (p<0.013). The study indicates nVNS can effectively block inflammation markers related to PTSD, showcasing potential in addressing unmet medical needs for the estimated 8 million Americans suffering from PTSD annually.
electroCore reports strong second quarter 2021 results with net sales of $1.3 million, up 69% year-over-year and 5% sequentially. Revenue from the VA and DoD increased 15% sequentially to $779,000. The company’s cash balance at June 30, 2021, stood at approximately $23.7 million, bolstered by a recent public offering yielding $18.8 million net proceeds. Despite a GAAP net loss of $2.9 million, this marks a 39% improvement from a year ago. The company anticipates third quarter revenue of at least $1.5 million.
On August 4, 2021, electroCore announced the publication of an article in PharmacoEconomics that highlights the cost-effectiveness of gammaCore for treating cluster headaches. It shows that gammaCore therapy can save £450 per patient in the first year compared to standard treatments, while also reducing headache frequency and severity. The UK National Institute for Health and Care Excellence (NICE) guidance supports the adoption of gammaCore in the NHS, aiming to enhance its market presence. Iain Strickland noted the significance of NICE’s endorsement for growth in the UK market.
On August 2, 2021, electroCore announced its participation in the Canaccord Genuity Growth Conference, set for August 10-12, 2021. The company's management will present on August 12 at 8:30 am EDT. This conference offers a platform for virtual one-on-one meetings with investors. Following the event, a recording of the presentation will be accessible on the investor section of the company's website. electroCore specializes in bioelectronic medicine, focusing on non-invasive vagus nerve stimulation therapies for neurological conditions, including migraine and cluster headaches.
electroCore (Nasdaq: ECOR) announced the issuance of U.S. Patent No. 11,065,444 by the USPTO, covering a mobile phone method for trigeminal nerve stimulation to treat disorders like migraines. This patent details devices enabling self-treatment through non-invasive electrical stimulation. The handheld device targets nerves in the head to alleviate conditions, enhancing access to treatment. This patent expands electroCore's non-invasive pain management program, reinforcing its commitment to improving patient outcomes.
electroCore, Inc. (NASDAQ: ECOR) will report its financial results for the second quarter ending June 30, 2021, on August 5, 2021, after market close. A conference call and webcast for discussion will take place at 4:30 PM ET on the same day. electroCore focuses on bioelectronic medicine, utilizing a non-invasive vagus nerve stimulation therapy platform aimed at treating conditions like migraines and cluster headaches. The company emphasizes its commitment to enhancing patient outcomes through this innovative treatment approach.
electroCore, Inc. (NASDAQ: ECOR) announced that its cofounder and Chief Medical Officer, Dr. Peter Staats, will receive a Lifetime Achievement Award at the American Society of Pain and Neuroscience Annual Conference on July 24th, 2021. This award recognizes Dr. Staats' significant contributions to pain medicine, including over 450 published works. He has held leadership roles in various medical societies and is currently the President Elect of the World Institute of Pain. electroCore focuses on non-invasive vagus nerve stimulation therapies for migraine and cluster headache treatment.
electroCore, Inc. (ECOR) expects approximately $1.3 million in revenue for Q2 2021, a 5% increase from Q1 2021 and a 69% growth year-over-year. The company reported a net cash usage of about $3.2 million for operations in the same period. As of June 30, 2021, cash and equivalents totaled approximately $23.7 million, which does not include $18.8 million raised in a recent offering. The company emphasizes ongoing operations and international expansion efforts.
electroCore, Inc. (Nasdaq: ECOR) will be presenting at the Ladenburg Thalmann 2021 Virtual Healthcare Conference on July 14, 2021, at 3:30 PM. CEO Dan Goldberger will provide a comprehensive overview of the company and engage in one-on-one meetings. Interested parties can access the presentation through the provided webcast link.
Following the event, a replay will be available in the Investor section of electroCore's website. The company specializes in non-invasive vagus nerve stimulation therapies aimed at treating cluster headaches and migraines.
